GRTX Galera Therapeutics Inc.: Earnings per one share for the last 12 months

Galera Therapeutics (GRTX) is concluding its operating cycle following the failure of a key drug; assessing the YoY TTM earnings per share dynamics on GURU.Markets, we find that the current level is approximately 19.20. The business relied on combating severe mucositis, while the high cost of trials and compound patents created a robust defensive barrier for the company.
Galera Therapeutics - analytical breakdowns and key metrics (GRTX)

The current YoY TTM net income per share growth reflects the business scaling efficiency of Galera Therapeutics (GRTX). This indicator measures the percentage change in earnings per common share over the last twelve months relative to the same period last year. The calculation is based on a comparison of aggregated TTM data to assess profitability growth rates. The automation of compound synthesis via AI complexes should optimize costs, directly impacting this metric. Positive dynamics confirm the capital's resilience to inflationary risks.